Check Claims Before You Publish

Known (from provided text): The study uses endonuclease-mediated Rasal1 impairment in WT vs Rasal1-impaired C57BL/6N mice, tests multiple murine tumor models (LLC1, MC38, B16F10, and B16F10-PDL1), and reports increased T cell activation/proliferation and improved tumor control after Rasal1 impairment. Rasal1 impairment study findings

Proposed mechanism (in the provided text): The described biology connects Rasal1 impairment to Ras/MAPK and downstream Akt/mTOR activation in CD8+ TILs and an enhanced Wnt/TCF1-linked stem-like program, culminating in increased cytolytic potential and PD-L1–suppression overcoming (with αPD-1 synergy in one model). Mechanistic pathway claims

Skeptical critique (what is underdetermined from the provided description):

• Attribution problem: The input explicitly notes that global impairment can affect non-immune cells, complicating claims that effects are solely due to T cell-intrinsic Rasal1 biology. Attribution limitation
• Translation uncertainty: The input states human translation is unproven and that prognostic correlations in bulk TCGA may be weak because immune vs tumor signal mixing reduces interpretability. Translation & TCGA mixing caution
• Model-dependent synergy: The αPD-1 synergy is reported for B16F10-PDL1 specifically; without broader αPD-1 synergy across other models in the provided description, generality remains uncertain. Synergy generalizability limitation

What would most strengthen confidence (falsification targets): The provided “how_to_falsify” list is consistent with a rigorous mechanistic standard: failure to increase intratumoral CD8+ TIL numbers/activation, failure to reproduce Ras/MAPK and Wnt signaling changes, failure to reduce tumor growth, failure of αPD-1 synergy, and failure to show consistent reproducible evidence across models/human correlations. Falsification criteria

The provided dataset contains multiple review-type works (e.g., orlistat/FASN multitarget review; calreticulin in phagocytosis/cancer immune outcomes review). Reviews are useful for organizing mechanistic hypotheses, but—without primary datasets in the input—cannot by themselves establish experimental causality or effect sizes in the target system. Mechanistic review framingContextual immune review

A primary research example is listed for ivermectin (“clinically feasible concentrations” repositioning), but the input does not provide enough methods/results detail to critically evaluate design quality (e.g., controls, endpoints, pharmacokinetic justification) beyond the author claim itself. Primary study listed (detail missing)